Previous 10 | Next 10 |
Gainers: Surface Oncology (NASDAQ: SURF ) +82% . More news on: Surface Oncology, Inc., Nabors Industries Ltd., LMP Automotive Holdings, Inc., Stocks on the move, , Read more ...
NuCana (NASDAQ: NCNA ): Q1 GAAP EPS of -£0.12 beats by £0.07 . More news on: NuCana plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
Clinical Studies Re-Opened to New Patient Enrollment Following Temporary Pause Due to COVID-19 Pandemic Numerous Clinical Data Announcements Expected in 2020 Cash and Cash Equivalents Expected to Fund Operations At Least into the Fourth Quarter of 2021 EDINBURGH, United K...
EDINBURGH, United Kingdom, May 18, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in multiple clinical studies following the temporary pause necessitated by the COVID-19 pandemic. NuCana previously announced the re-opening of its ...
Non-Clinical Findings Suggest that Acelarin and NUC-3373 May Induce an Immune Response Against Cancer Cells Acelarin (NUC-1031) Releases DAMPs and Upregulates PD-L1 Expression in Lung Cancer Cells NUC-3373 Induces Endoplasmic Reticulum Stress and Release of DAMPs in Colorectal Ca...
EDINBURGH, U.K., May 05, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in NuTide:121, its ongoing global Phase III study of Acelarin (NUC-1031) plus cisplatin in patients with biliary tract cancer. The re-opening of NuTide:121 has b...
EDINBURGH, United Kingdom, April 02, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) has been closely monitoring the potential impact of the COVID-19 pandemic on its operations and announced today an update on the status of its ongoing clinical studies. In order to help to protect the...
Gainers: DXC +34.3% . ALT +20.7% . CNDT +14.6% . CLDR +12.1% . NCNA +10.2% . More news on: DXC Technology Company, Altimmune, Inc., Conduent Incorporated, Stocks on the move, , News on ETFs Read more ...
Preliminary data from a Phase 2 clinical trial evaluating NuCana's (NASDAQ: NCNA ) Acelarin (NUC-1031) in heavily pretreated patients with platinum-resistant ovarian cancer showed a treatment effect. More news on: NuCana plc, Healthcare stocks news, Stocks on the move, Read more ....
NuCana (NASDAQ: NCNA ): Q4 GAAP EPS of -£0.24 misses by £0.08 . More news on: NuCana plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, ...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthca...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer...